Caplight Directory>Companies>AirNexis Therapeutics-preview>Airnexis


AirNexis Therapeutics

AirNexis Therapeutics

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://airnexis.com

Last Round

Series A

Mar 9, 2026

Est. Valuation

$341.7M

Total Funding Raised

$200M

Company Overview

AirNexis Therapeutics is a biotechnology company developing clinical-stage therapies for chronic obstructive pulmonary disease (COPD) and other pulmonary conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

COPD treatmentPDE3/4 inhibitorCOPDdual phosphodiesterase 3 and 4 inhibitorChronic Obstructive Pulmonary Diseasepulmonary therapeuticsinhaled therapeuticclinical-stage biotechasset-centric biotechPhase II clinical trialsingle asset biotechsmall molecule drugdrug in-licensinganti-inflammatory drugbronchodilatorrespiratory medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AirNexis Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AirNexis Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMar 9, 2026
Series AJan 9, 2026
View all Funding Rounds

AirNexis Therapeutics Investors

Notable investors and investment history

InvestorRounds
Longitude CapitalSeries A
Enavate SciencesSeries A
Life Sciences at Goldman Sachs AlternativesSeries A
OrbiMedSeries A
Frazier Life SciencesSeries A
SR OneSeries A
Goldman Sachs AlternativesSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 9, 2026

    $62M round completed.

View all signals

AirNexis Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AirNexis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AirNexis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Year Founded2025
Last FundingMar 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.